rs780096 — GCKR GCKR Metabolic Balance Variant

Intronic GCKR enhancer variant that modulates FOXA2-driven GCKR expression in liver; the C allele reduces GCKR expression and weakens hepatic glucokinase braking, contributing to the glucose-triglyceride trade-off pattern characteristic of the GCKR locus — lower fasting glucose and insulin at the cost of elevated triglycerides and NAFLD susceptibility

See your personal result for GCKR

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

GCKR rs780096 — The Enhancer Allele Behind the Glucokinase Trade-Off

Glucokinase regulatory protein (GCKRP), encoded by GCKR on chromosome 2, acts as a brake on hepatic glucokinase — the enzyme that drives the liver's glucose uptake after meals. The rs780096 variant sits within an intronic enhancer that controls how much GCKRP the liver produces. The G allele of rs780096 anchors the CGG haplotype11 CGG haplotype
Three-SNP cluster spanning rs780094, rs780095, rs780096 — all in strong linkage disequilibrium within a short intronic region of GCKR, which drives higher FOXA2-dependent GCKR transcription in liver cells. The C allele forms the TAC haplotype, which produces less GCKRP and therefore exerts a weaker brake on hepatic glucokinase — contributing to the same glucose-lowering, triglyceride-raising metabolic pattern seen across the GCKR locus.

This is a regulatory variant. Unlike the well-characterized rs1260326 Pro446Leu22 rs1260326 Pro446Leu
Coding missense variant in GCKR that directly reduces GCKRP's sensitivity to fructose-6-phosphate, leaving glucokinase constitutively more active variant that acts by reducing the GCKRP protein's inhibitory function, rs780096 modulates the amount of GCKRP produced. The two variants are not in perfect LD — rs780096 captures an independent layer of GCKR regulation.

The Mechanism

A 2017 Genome Medicine study33 2017 Genome Medicine study
López Rodríguez, Kaminska et al., Kaikkonen and Laakso groups, University of Eastern Finland mapped a liver-specific transcriptional enhancer in the GCKR intron containing rs780094, rs780095, and rs780096. The CGG haplotype (G at rs780096) showed approximately twofold higher transcriptional activity in luciferase reporter assays and displayed elevated H3K27Ac histone marks — a hallmark of active enhancer chromatin. FOXA2, a liver-enriched transcription factor critical for hepatic glucose and lipid homeostasis, bound this region in a haplotype-specific manner (CGG > TAC), and CRISPR-based epigenetic activation of the enhancer directly increased endogenous GCKR transcript levels. Human liver biopsies confirmed the CGG haplotype transcribes more GCKR RNA in vivo.

The metabolic logic follows from this: more GCKRP (CGG/G allele) means a stronger brake on glucokinase during fasting, keeping hepatic glucose uptake lower and fasting glucose somewhat higher while reducing the lipogenic flux that generates triglycerides. Less GCKRP (TAC/C allele) means a weaker brake, allowing more glucokinase activity, lower fasting glucose, and — through increased glycolytic flux, malonyl-CoA, and citrate production — elevated de novo lipogenesis44 de novo lipogenesis
The liver's conversion of carbohydrate precursors into fatty acids and VLDL-triglycerides.

The four-SNP haplotype incorporating rs1260326 (P446L) paints the full picture: CGGC haplotype (G at rs780096, C at rs1260326 = ancestral Pro446) = maximum GCKRP expression with functional inhibitory protein; TACT haplotype (C at rs780096, T at rs1260326 = Leu446) = reduced GCKRP expression plus a less effective inhibitory protein. These two changes compound each other at the locus.

The Evidence

The primary mechanistic evidence for rs780096's enhancer role comes from López Rodríguez et al. 2017, which used luciferase assays, CRISPR activation, and human liver biopsy data to establish the CGG haplotype's regulatory effect. Effect magnitude55 Effect magnitude
The paper reports ~twofold or greater transcriptional activity for CGG vs TAC in HepG2 and primary hepatocytes; FOXA2 co-transfection amplified the difference.

The metabolic phenotype evidence comes from studies of the tightly linked rs780094 and rs1260326, which co-segregate on the same TACT haplotype as the rs780096 C allele. The ARIC Study (n=14,889)66 ARIC Study (n=14,889)
Atherosclerosis Risk in Communities Study; Köttgen et al. 2010 quantified per-allele effects of the lipogenic GCKR haplotype: −1.93 mg/dl fasting glucose (P=2.3×10⁻⁷), +0.16 mmol/l triglycerides (P=2.4×10⁻³¹), −0.45 HOMA-IR (P=2.2×10⁻⁹), and +0.56 mg/l CRP (P=1.6×10⁻⁸) in white participants. Sparsø et al. 2008 in 16,853 Danes found fasting triglyceride elevation (P=6×10⁻¹⁴) and reduced insulinaemia77 fasting triglyceride elevation (P=6×10⁻¹⁴) and reduced insulinaemia
Linked to the same lipogenic GCKR haplotype with modestly reduced T2D risk.

Gene-diet interactions at the GCKR locus are well documented. Tam et al. 201588 Tam et al. 2015
Study of 660 healthy adolescents; nutrition assessed by food frequency questionnaire found that high fish consumption (rich in omega-3) significantly reduced triglycerides in carriers of the lipogenic GCKR allele. Perez-Martinez et al. 201199 Perez-Martinez et al. 2011
LIPGENE dietary cohort, n=379 metabolic syndrome subjects; plasma omega-3 PUFA measured showed the GCKR risk allele group were "high responders" to omega-3: elevated plasma omega-3 reduced fasting insulin (P=0.019), HOMA-IR (P=0.008), and CRP (P=0.032) selectively in risk allele carriers, suggesting omega-3 supplementation is particularly effective for this genotype.

Practical Actions

The C allele at rs780096 contributes to the same GCKR lipogenic phenotype as the T allele at rs780094 and rs1260326: reduced GCKRP output lowers the brake on hepatic glucokinase, channelling more glucose carbon into fat synthesis. Dietary fructose restriction is the most mechanistically targeted response, since fructose bypasses the rate-limiting phosphofructokinase step and floods the hepatic lipogenic pathway that becomes overactive when GCKRP levels are low. Omega-3 fatty acids (EPA and DHA) suppress VLDL-triglyceride secretion and de novo lipogenesis transcriptionally, and gene-diet interaction data specifically supports their benefit in GCKR risk allele carriers. Fasting triglyceride monitoring provides early warning of worsening lipid profiles before cardiovascular or hepatic risk accumulates.

Interactions

rs780096 is part of a four-SNP haplotype with rs780094, rs780095, and rs1260326 (P446L). The C allele at rs780096 co-segregates with the T allele at rs780094 and rs1260326 on the TACT/lipogenic haplotype. Individuals carrying the C allele here very frequently also carry the T (lipogenic) allele at rs780094 — these variants are not perfectly correlated, but their functional effects compound. The strongest documented gene-gene interaction at this locus is with PNPLA3 rs738409 (G allele): dual carriers of the GCKR lipogenic allele and the PNPLA3 NAFLD allele carry substantially higher hepatic steatosis burden than either alone. The GCK promoter variant rs1799884 interacts with GCKR rs780094 on fasting plasma glucose in Chinese populations; a similar compound effect likely applies to rs780096 C allele carriers.

Nutrient Interactions

fructose altered_metabolism
refined carbohydrates altered_metabolism
omega-3 fatty acids (EPA/DHA) increased_need

Genotype Interpretations

What each possible genotype means for this variant.

GG Full GCKR Expression Normal

Both copies of the enhancer G allele — standard hepatic GCKR expression and normal glucokinase braking

You carry two copies of the G allele at rs780096, which anchors the CGG enhancer haplotype associated with higher FOXA2-driven GCKR expression in liver cells. Both copies of your GCKR enhancer drive normal to higher levels of GCKRP production, maintaining standard inhibitory control over hepatic glucokinase. About 30% of people share this GG genotype globally, though it is substantially more common in East Asians (~81%). Your fasting glucose, triglyceride tendency, and NAFLD risk are not elevated through this locus.

CG Partial Enhancer Reduction Intermediate

One C allele — modestly reduced GCKR enhancer activity, with mild tendency toward lower fasting glucose and slightly elevated triglycerides

The CG genotype reflects a partial reduction in GCKR enhancer output. Because one enhancer allele (G) drives normal GCKRP expression and the other (C) drives reduced expression, the net GCKRP level is intermediate between GG and CC. With moderately less GCKRP braking hepatic glucokinase, there is a mild increase in glycolytic flux through the liver that can elevate de novo lipogenesis and VLDL- triglyceride secretion. The effect is roughly half the magnitude expected in CC homozygotes. Gene-diet interaction data from the linked GCKR locus variants suggests that high fish intake (omega-3 fatty acids) and limiting dietary fructose are particularly effective interventions for the GCKR lipogenic phenotype.

CC Reduced GCKR Enhancer Output High Risk

Two C alleles — maximally reduced GCKR enhancer activity, with lower fasting glucose and the highest triglyceride and NAFLD susceptibility at this locus

With both GCKR enhancer alleles in the low-expression TAC configuration, hepatic GCKRP levels are maximally reduced from this locus. Less GCKRP protein means weaker inhibitory control over glucokinase, keeping the enzyme constitutively more active and driving greater glycolytic flux through the liver. The downstream consequence is increased malonyl-CoA and citrate production — the direct precursors to de novo lipogenesis — which elevates VLDL-triglyceride secretion and predisposes to hepatic steatosis (NAFLD).

The reduced fasting glucose and insulin resistance are genuine advantages. The clinical challenge is managing the triglyceride and hepatic fat burden without undermining the insulin-sensitivity benefit.

Because rs780096 C allele co-segregates with the rs780094 T allele and rs1260326 T (Pro446Leu) allele on the TACT haplotype, CC homozygotes at rs780096 very frequently also carry the lipogenic alleles at those linked positions — compounding the magnitude of GCKRP dysfunction (reduced amount of protein and reduced inhibitory effectiveness per protein molecule). Dietary fructose restriction and therapeutic-dose omega-3 supplementation are the most evidence-backed interventions for this genotype combination.